
Herpes Zoster Treatment Market Growth, Size, Trends, Demand, Share, Revenue and Future Outlook
Herpes Zoster Treatment Market Size- By Route Of Administration, By Treatment Type, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
Published: Dec-2022 | Report ID: HLCA2221 | Pages: 1 - 238 | Formats*: |
Category : Healthcare |
- December 2022; The Food and Drug Administration of the Philippines has approved the clinical study for Jiangsu Recbio Technology Co., Ltd.'s innovative adjuvanted recombinant shingles vaccine, REC610.
- September 2022; The US Food and Drug Administration has given Zydus Lifesciences approval to sell Pregabalin extended-release pills, which are used to treat pain brought on by nerve damage from shingles (herpes zoster) infections or diabetes.
-006033916052024.webp)
-006033016052024.webp)
Report Metric | Details |
Market size available for years | 2019-2032 |
Base year considered | 2021 |
Forecast period | 2022-2032 |
Segments covered | By Treatment Type, By Route of Administration, By Distribution Channel |
Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Companies Covered | Abbott Laboratory, Bausch Health, Cipla Inc, Camber Pharmaceuticals, GlaxoSmithKline plc, Merck & Co, Novartis AG, Pfizer Inc, Eli Lilly and Co, Teva Pharmaceutical Industries Ltd |
- Adults aged 50 and over
- Healthcare professionals (HCPs)
- Immunocompromised individuals
- People with chronic health conditions
- Government agencies
- Non-profit organizations
- Pharmaceutical companies
- Vaccine manufacturers
- Diagnostic test manufacturers
- Medical device companies
By Treatment Type: | |
By Route of Administration: | |
By Distribution Channel: |
- Global Herpes Zoster Treatment Market Size (FY’2022-FY’2032)
- Overview of Global Herpes Zoster Treatment Market
- Segmentation of Global Herpes Zoster Treatment Market By Treatment Type (Antiviral Medications, Anti-inflammatory, Medications, Others)
- Segmentation of Global Herpes Zoster Treatment Market By Route of Administration (Oral, Topical)
- Segmentation of Global Herpes Zoster Treatment Market By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers)
- Statistical Snap of Global Herpes Zoster Treatment Market
- Expansion Analysis of Global Herpes Zoster Treatment Market
- Problems and Obstacles in Global Herpes Zoster Treatment Market
- Competitive Landscape in the Global Herpes Zoster Treatment Market
- Impact of COVID-19 and Demonetization on Global Herpes Zoster Treatment Market
- Details on Current Investment in Global Herpes Zoster Treatment Market
- Competitive Analysis of Global Herpes Zoster Treatment Market
- Prominent Players in the Global Herpes Zoster Treatment Market
- SWOT Analysis of Global Herpes Zoster Treatment Market
- Global Herpes Zoster Treatment Market Future Outlook and Projections (FY’2022-FY’2032)
- Recommendations from Analyst
1.1. Scope of the report1.2. Market segment analysis
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Herpes Zoster Treatment Market
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6.1. Global Herpes Zoster Treatment Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Herpes Zoster Treatment Market
7.1. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Treatment Type, 2019-20257.2. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Treatment Type, 2026-20327.3. Antiviral Medications7.4. Anti-inflammatory7.5. Medications7.6. Others
8.1. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Route of Administration, 2019-20258.2. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Route of Administration, 2026-20328.3. Oral8.4. Topical
9.1. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Distribution Channel, 2019-20259.2. Global Herpes Zoster Treatment Market Size, Share and Forecast, By Distribution Channel, 2026-20329.3. Hospital Pharmacies9.4. Drug Stores & Retail Pharmacies9.5. Online Providers
10.1. Global Herpes Zoster Treatment Market Size and Market Share
11.1. Global Herpes Zoster Treatment Market Size and Market Share By Region (2019-2025)11.2. Global Herpes Zoster Treatment Market Size and Market Share By Region (2026-2032)11.3. Asia-Pacific
11.3.1. Australia11.3.2. China11.3.3. India11.3.4. Japan11.3.5. South Korea11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France11.4.2. Germany11.4.3. Italy11.4.4. Spain11.4.5. United Kingdom11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia11.5.2. United Arab Emirates11.5.3. Qatar11.5.4. South Africa11.5.5. Egypt11.5.6. Morocco11.5.7. Nigeria11.5.8. Rest of Middle East & Africa
11.6. North America
11.6.1. Canada11.6.2. Mexico11.6.3. United States
11.7. Latin America
11.7.1. Argentina11.7.2. Brazil11.7.3. Rest of Latin America
12.1. Abbott Laboratory
12.1.1. Company details12.1.2. Financial outlook12.1.3. Product summary12.1.4. Recent developments
12.2. Bausch Health
12.2.1. Company details12.2.2. Financial outlook12.2.3. Product summary12.2.4. Recent developments
12.3. Cipla Inc.
12.3.1. Company details12.3.2. Financial outlook12.3.3. Product summary12.3.4. Recent developments
12.4. Camber Pharmaceuticals.
12.4.1. Company details12.4.2. Financial outlook12.4.3. Product summary12.4.4. Recent developments
12.5. GlaxoSmithKline plc.
12.5.1. Company details12.5.2. Financial outlook12.5.3. Product summary12.5.4. Recent developments
12.6. Merck & Co.,
12.6.1. Company details12.6.2. Financial outlook12.6.3. Product summary12.6.4. Recent developments
12.7. Novartis AG.
12.7.1. Company details12.7.2. Financial outlook12.7.3. Product summary12.7.4. Recent developments
12.8. Pfizer Inc.
12.8.1. Company details12.8.2. Financial outlook12.8.3. Product summary12.8.4. Recent developments
12.9. Eli Lilly and Co.
12.9.1. Company details12.9.2. Financial outlook12.9.3. Product summary12.9.4. Recent developments
12.10. Teva Pharmaceutical Industries Ltd.
12.10.1. Company details12.10.2. Financial outlook12.10.3. Product summary12.10.4. Recent developments
12.11. Others
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment






Related Reports
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.